2025 Japan Allergy Immunotherapy Revenue Opportunities Report
Description
The 2025 Japan Allergy Immunotherapy Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the allergy immunotherapy market in Japan are ALK-Abelló, Stallergenes Greer, Takeda Pharmaceutical Company Limited, and Eisai Co. ALK-Abelló, a global leader in allergy vaccination, collaborates with Torii Pharmaceutical to market allergy immunotherapy products such as MITIZAX® targeting house dust mite and Japanese cedar pollen allergies in Japan. Stallergenes Greer offers sublingual immunotherapy tablets like Actair® for house dust mite-induced allergic rhinitis, with promotion transitioning through local partners like Shionogi and CEOLIA Pharma. Takeda and Eisai are major pharmaceutical players in Japan’s allergy therapeutics market, contributing to a growing market expected to reach $2.46 billion by 2030.
These companies focus on both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), with SLIT treatments, such as allergen tablets and drops, showing rapid growth in Japan. For example, SCIT and SLIT are approved for Japanese cedar pollen and house dust mite allergies, with products like Cedarcure and Miticure gaining market approval. The market growth of 8.7% CAGR and rising allergy prevalence drive investments and partnerships, with ALK-Abelló enhancing market penetration and Stallergenes Greer emphasizing personalized immunotherapy solutions to improve patient outcomes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the allergy immunotherapy market in Japan are ALK-Abelló, Stallergenes Greer, Takeda Pharmaceutical Company Limited, and Eisai Co. ALK-Abelló, a global leader in allergy vaccination, collaborates with Torii Pharmaceutical to market allergy immunotherapy products such as MITIZAX® targeting house dust mite and Japanese cedar pollen allergies in Japan. Stallergenes Greer offers sublingual immunotherapy tablets like Actair® for house dust mite-induced allergic rhinitis, with promotion transitioning through local partners like Shionogi and CEOLIA Pharma. Takeda and Eisai are major pharmaceutical players in Japan’s allergy therapeutics market, contributing to a growing market expected to reach $2.46 billion by 2030.
These companies focus on both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), with SLIT treatments, such as allergen tablets and drops, showing rapid growth in Japan. For example, SCIT and SLIT are approved for Japanese cedar pollen and house dust mite allergies, with products like Cedarcure and Miticure gaining market approval. The market growth of 8.7% CAGR and rising allergy prevalence drive investments and partnerships, with ALK-Abelló enhancing market penetration and Stallergenes Greer emphasizing personalized immunotherapy solutions to improve patient outcomes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
